Fulcrum Therapeutics FULC 深 沪
等待开盘 08-13 09:30:00 美东时间
6.54
+0.200
+3.15%
华盛通- 最 高6.58
- 今 开6.39
- 成交量 44.33万股
- 最 低 6.28
- 昨 收 6.34
- 总市值 3.53亿
- 52周最高 9.90
- 市盈率 静 --
- 换手率 0.82%
- 52周最低 2.315
- 委 比 -61.59%
- 总股本 5397.93万
- 历史最高 33.098
- 量 比 0.81
- 振 幅 4.73%
- 历史最低 2.25
- 每 手 1
- 风险率 1.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Fulcrum defended at H.C. Wainwright after data for sickle cell disease drug
Fulcrum Therapeutics (NASDAQ:FULC) fell ~10% on Tuesday after the company posted data from a late-stage study of its lead candidate, Pociredir, in sickle cell disease, along with second quarter result...
07-30 01:38
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025
Fulcrum Therapeutics reported positive interim results from a 12 mg cohort of the Phase 1b PIONEER trial evaluating pociredir in sickle cell disease (SCD). In the 12-week treatment period, patients experienced significant increases in fetal hemoglobin (HbF), with a 8.6% mean increase and 67% mean of F-cells. Improvements were also observed in markers of hemolysis and total hemoglobin levels. Pociredir was well-tolerated, with no drug-related seri...
07-29 10:48
Fulcrum Therapeutics To Present Topline Results From 12 Mg Dose Cohort Of Phase 1b PIONEER Trial Of Pociredir In Sickle Cell Disease
Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will
07-29 04:02
Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Fulcrum Therapeutics will host a conference call on July 29, 2025 to present Phase 1b PIONEER trial results for pociredir in sickle cell disease (SCD). The event will feature management alongside medical experts. Pociredir aims to increase fetal hemoglobin (HbF) through EED inhibition. SCD, a genetic disorder causing sickle-shaped red blood cells, leads to severe health issues. The results may highlight potential benefits for SCD patients. For mo...
07-28 20:01
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>Fulcrum Therapeutics granted non-statutory stock options to a new employee under its 2022 Inducement Stock Incentive Plan. The employee received 70,000 options with an exercise price of $6.96 per share, vesting over four years. Fulcrum is a clinical-stage biopharmaceutical company focused on developing small molecules for rare genetic diseases.</p>
06-06 20:30
美股大行评级 | 潜在涨幅746.15%！Intrusion获Ascendiant Capital升目标价至11美元，维持"买入"评级
潜在涨幅746.15%！Intrusion获Ascendiant Capital升目标价至11美元，维持"买入"评级
06-02 13:32
美股大行评级 | 英伟达、赛富时、C3.ai、Veeva Systems等获多家机构上调目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1135136987677396993.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Cogent Biosciences(COGT)"超配"评级，目标价从21美元升至25美元</p> <p>• Chardan Capital：维持Taysha Gene Therapies(TSHA)"买入"
05-30 09:09
Fulcrum Therapeutics to Present at Upcoming Medical Meetings
Fulcrum Therapeutics will present updates on their lead compound, pociredir, a novel oral fetal hemoglobin inducer for the treatment of sickle cell disease (SCD), at the 5th Global Congress on Sickle Cell Disease and the 2025 European Hematology Association Congress. The presentations will include preclinical and early clinical results, as well as data from Phase 1 studies assessing safety, pharmacokinetics, and pharmacodynamics. Pociredir aims t...
05-29 20:10
Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
Fulcrum Therapeutics announced that its management will participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference on June 11, 2025. The webcast will be accessible via the links provided, and a replay will be available on the company's website for 30 days. Fulcrum Therapeutics focuses on developing small molecules for rare genetic diseases, with its lead program targeting sickle cell disease.
05-29 12:30
美股大行评级 | 潜在涨幅112.77%！Craig-Hallum上调PLAYSTUDIOS目标价至3美元，评级升至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1132955525493317632.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Craig-Hallum：上调PLAYSTUDIOS(MYPS)评级至"买入"，目标价从2美元升至3美元</p> <p>• Leerink Partners：上调Fulcrum Therapeutics(FULC)评级至"
05-24 08:40
